Connection

Michael Hallek to Maintenance Chemotherapy

Back to Details
This is a "connection" page, showing publications Michael Hallek has written about Maintenance Chemotherapy.
Michael Hallek
Connection Strength
0.411
Maintenance Chemotherapy
  1. CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol. 2018 Mar; 14(6):499-513.
    View in: PubMed
    Score: 0.171
  2. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct; 4(10):e475-e486.
    View in: PubMed
    Score: 0.166
  3. New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. Leuk Lymphoma. 2019 03; 60(3):649-657.
    View in: PubMed
    Score: 0.045
  4. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 09; 367(6):520-31.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.